{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:30:20Z","timestamp":1782135020613,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016395","name":"National Center for Special Education Research, Institute of Education Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05528-7","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T15:02:26Z","timestamp":1707836546000},"page":"643-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Progression of subclinical atherosclerosis in ankylosing spondylitis: a 10-year prospective study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-1518","authenticated-orcid":false,"given":"Aikaterini","family":"Arida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-8263","authenticated-orcid":false,"given":"Dimitrios","family":"Terentes-Printzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Konstantonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3825-532X","authenticated-orcid":false,"given":"Athanasios D.","family":"Protogerou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-3558","authenticated-orcid":false,"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"5528_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071890","author":"A Arida","year":"2018","unstructured":"Arida A, Protogerou AD, Kitas GD, Sfikakis PP (2018) Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19071890","journal-title":"Int J Mol Sci"},{"key":"5528_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2021-221733","author":"GC Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2021-221733","journal-title":"Ann Rheum Dis"},{"key":"5528_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"key":"5528_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa246","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Robertson S, Reich T et al (2020) Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaa246","journal-title":"Rheumatology"},{"key":"5528_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/S10067-023-06655-Z","author":"R Hintenberger","year":"2023","unstructured":"Hintenberger R, Affenzeller B, Vladychuk V, Pieringer H (2023) Cardiovascular risk in axial spondyloarthritis-a systematic review. Clin Rheumatol. https:\/\/doi.org\/10.1007\/S10067-023-06655-Z","journal-title":"Clin Rheumatol"},{"key":"5528_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/14712598.2020.1704727","volume":"20","author":"F Atzeni","year":"2020","unstructured":"Atzeni F, Nucera V, Galloway J et al (2020) Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther 20:517\u2013524. https:\/\/doi.org\/10.1080\/14712598.2020.1704727","journal-title":"Expert Opin Biol Ther"},{"key":"5528_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jbspin.2013.03.019","volume":"81","author":"C Papagoras","year":"2014","unstructured":"Papagoras C, Markatseli TE, Saougou I et al (2014) Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine 81:57\u201363. https:\/\/doi.org\/10.1016\/j.jbspin.2013.03.019","journal-title":"Jt Bone Spine"},{"key":"5528_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/annrheumdis-2019-eular.3746","volume":"38","author":"J Rueda-Gotor","year":"2020","unstructured":"Rueda-Gotor J, Quevedo-Abeledo JC, Corrales A et al (2020) Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis. Clin Exp Rheumatol 38:724\u2013731. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.3746","journal-title":"Clin Exp Rheumatol"},{"key":"5528_CR9","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.3899\/jrheum.150316","volume":"42","author":"A Arida","year":"2015","unstructured":"Arida A, Protogerou AD, Konstantonis G et al (2015) Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol 42:2098\u20132105. https:\/\/doi.org\/10.3899\/jrheum.150316","journal-title":"J Rheumatol"},{"key":"5528_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1194\/JLR.R600021-JLR200","volume":"48","author":"C Popa","year":"2007","unstructured":"Popa C, Netea MG, Van Riel PLCM et al (2007) The role of TNF-\u03b1 in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751\u2013762. https:\/\/doi.org\/10.1194\/JLR.R600021-JLR200","journal-title":"J Lipid Res"},{"key":"5528_CR11","doi-asserted-by":"publisher","first-page":"730.e9","DOI":"10.1016\/j.amjmed.2013.02.016","volume":"126","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Curtis JR, Saag KG et al (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs. Am J Med 126:730.e9-730.e17. https:\/\/doi.org\/10.1016\/j.amjmed.2013.02.016","journal-title":"Am J Med"},{"key":"5528_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/rheumatology\/kew506","volume":"56","author":"A. A, A.D. P, G. K,","year":"2017","unstructured":"A. A, A.D. P, G. K, et al (2017) Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology 56:934\u2013939. https:\/\/doi.org\/10.1093\/rheumatology\/kew506","journal-title":"Rheumatology"},{"key":"5528_CR13","first-page":"373","volume":"24","author":"MA Gonzalez-Gay","year":"2006","unstructured":"Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM et al (2006) Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:373\u2013379","journal-title":"Clin Exp Rheumatol"},{"key":"5528_CR14","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.2147\/JIR.S282691","volume":"14","author":"GE Fragoulis","year":"2021","unstructured":"Fragoulis GE, Soulaidopoulos S, Sfikakis PP et al (2021) Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction. J Inflamm Res 14:1915. https:\/\/doi.org\/10.2147\/JIR.S282691","journal-title":"J Inflamm Res"},{"key":"5528_CR15","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/acr.22302","volume":"66","author":"CM Bartels","year":"2014","unstructured":"Bartels CM, Johnson H, Voelker K et al (2014) Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care. Arthritis Care Res (Hoboken) 66:1281\u20131288. https:\/\/doi.org\/10.1002\/acr.22302","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5528_CR16","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar4324","volume":"15","author":"AD Protogerou","year":"2013","unstructured":"Protogerou AD, Panagiotakos DB, Zampeli E et al (2013) Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 15:R142. https:\/\/doi.org\/10.1186\/ar4324","journal-title":"Arthritis Res Ther"},{"key":"5528_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/ART.1780270401","volume":"27","author":"LS Van Der","year":"1984","unstructured":"Van Der LS, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368. https:\/\/doi.org\/10.1002\/ART.1780270401","journal-title":"Arthritis Rheum"},{"key":"5528_CR18","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"5528_CR19","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"5528_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/EURJPC\/ZWAB154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2022) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 29:5\u2013115. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAB154","journal-title":"Eur J Prev Cardiol"},{"key":"5528_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132307","author":"AD Protogerou","year":"2015","unstructured":"Protogerou AD, Fransen J, Zampeli E et al (2015) The additive value of femoral ultrasound for subclinical atherosclerosis assessment in a single center cohort of 962 adults, including high risk patients with rheumatoid arthritis, Human Immunodeficiency Virus infection and Type 2 Diabetes Mellitus. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0132307","journal-title":"PLoS ONE"},{"key":"5528_CR22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1161\/ATVBAHA.109.190108","volume":"29","author":"KS Stamatelopoulos","year":"2009","unstructured":"Stamatelopoulos KS, Kitas GD, Papamichael CM et al (2009) Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 29:1702\u20131708. https:\/\/doi.org\/10.1161\/ATVBAHA.109.190108","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5528_CR23","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/EURHEARTJ\/EHAB309","volume":"42","author":"S Hageman","year":"2021","unstructured":"Collaboration S working group and EC risk, Hageman S, Pennells L et al (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42:2439\u20132454. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB309","journal-title":"Eur Heart J"},{"key":"5528_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","volume":"74","author":"AM van Sijl","year":"2015","unstructured":"van Sijl AM, van Eijk IC, Peters MJL et al (2015) Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 74:119\u2013123. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203934","journal-title":"Ann Rheum Dis"},{"key":"5528_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/HYPERTENSIONAHA.117.09633","volume":"70","author":"D Terentes-Printzios","year":"2017","unstructured":"Terentes-Printzios D, Vlachopoulos C, Xaplanteris P et al (2017) Cardiovascular risk factors accelerate progression of vascular aging in the general population: results from the CRAVE study (cardiovascular risk factors affecting vascular age). Hypertens (Dallas, Tex 1979) 70:1057\u20131064. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09633","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"5528_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.HJC.2023.05.008","author":"S Wu","year":"2023","unstructured":"Wu S, Su X, Zuo Y et al (2023) Discordance between remnant cholesterol and low-density lipoprotein cholesterol predicts arterial stiffness progression. Hellenic J Cardiol. https:\/\/doi.org\/10.1016\/J.HJC.2023.05.008","journal-title":"Hellenic J Cardiol"},{"key":"5528_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/J.HJC.2023.07.009","author":"X Tian","year":"2023","unstructured":"Tian X, Chen S, Wang P et al (2023) The impact of serum acid, arterial stiffness, and hypertension as a mediating factor: a cohort study. Hellenic J Cardiol. https:\/\/doi.org\/10.1016\/J.HJC.2023.07.009","journal-title":"Hellenic J Cardiol"},{"key":"5528_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAD184","author":"N Papazoglou","year":"2023","unstructured":"Papazoglou N, Kravvariti E, Konstantonis G et al (2023) The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAD184","journal-title":"Rheumatology (Oxford)"},{"key":"5528_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117952","volume":"10","author":"LR Baghdadi","year":"2015","unstructured":"Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA (2015) The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE 10:e0117952. https:\/\/doi.org\/10.1371\/journal.pone.0117952","journal-title":"PLoS ONE"},{"key":"5528_CR30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/JAMA.2022.13044","volume":"328","author":"CM Mangione","year":"2022","unstructured":"Mangione CM, Barry MJ, Nicholson WK et al (2022) Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA 328:746\u2013753. https:\/\/doi.org\/10.1001\/JAMA.2022.13044","journal-title":"JAMA"},{"key":"5528_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","volume":"34","author":"MJ Peters","year":"2004","unstructured":"Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585\u2013592","journal-title":"Semin Arthritis Rheum"},{"key":"5528_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213317","author":"S Mathieu","year":"2018","unstructured":"Mathieu S, Soubrier M (2018) Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis. Ann Rheum Dis Annrheumdis. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213317","journal-title":"Ann Rheum Dis Annrheumdis"},{"key":"5528_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2022.109207","volume":"112","author":"JX Huang","year":"2022","unstructured":"Huang JX, Lee YH, Cheng-Chung Wei J (2022) Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis. Int Immunopharmacol 112:109207. https:\/\/doi.org\/10.1016\/J.INTIMP.2022.109207","journal-title":"Int Immunopharmacol"},{"key":"5528_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/rheumatology\/ket454","volume":"53","author":"L-S Tam","year":"2014","unstructured":"Tam L-S, Kitas GD, Gonzalez-Gay MA (2014) Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology 53:1108\u20131119. https:\/\/doi.org\/10.1093\/rheumatology\/ket454","journal-title":"Rheumatology"},{"key":"5528_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/rheumatology\/kes272","volume":"52","author":"S Mathieu","year":"2013","unstructured":"Mathieu S, Pereira B, Couderc M et al (2013) No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatol (United Kingdom) 52:204\u2013209. https:\/\/doi.org\/10.1093\/rheumatology\/kes272","journal-title":"Rheumatol (United Kingdom)"},{"key":"5528_CR36","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/HYPERTENSIONAHA.109.143982","volume":"55","author":"K Angel","year":"2010","unstructured":"Angel K, Provan SA, Gulseth HL et al (2010) Tumor necrosis factor-\u03b1 antagonists improve aortic stiffness in patients with inflammatory Arthropathies. Hypertension 55:333\u2013338. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.143982","journal-title":"Hypertension"},{"key":"5528_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00296-019-04497-0","volume":"40","author":"E V\u00e9gh","year":"2020","unstructured":"V\u00e9gh E, Kerekes G, Pusztai A et al (2020) Effects of 1-year anti-TNF-\u03b1 therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol Int 40:427\u2013436. https:\/\/doi.org\/10.1007\/s00296-019-04497-0","journal-title":"Rheumatol Int"},{"key":"5528_CR38","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1097\/00004872-199816121-00033","volume":"16","author":"IB Wilkinson","year":"1998","unstructured":"Wilkinson IB, Fuchs SA, Jansen IM et al (1998) Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 16:2079\u20132084. https:\/\/doi.org\/10.1097\/00004872-199816121-00033","journal-title":"J Hypertens"},{"key":"5528_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jacc.2013.10.040","volume":"63","author":"C Vlachopoulos","year":"2014","unstructured":"Vlachopoulos C, Aznaouridis K, Stefanadis C (2014) Aortic stiffness for cardiovascular risk prediction: just measure it, just do it! J Am Coll Cardiol 63:647\u2013649. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.040","journal-title":"J Am Coll Cardiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05528-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T21:37:20Z","timestamp":1709933840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05528-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5528"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05528-7","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest and the study was complied with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}